In Billing
Nov 14th, 2011
Effective June 30, 2011, the Centers for Medicare & Medicaid Services (CMS) will cover autologous cellular immunotherapy treatment for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. Sipuleucel-T (PROVENGE®) is the first immunotherapy for prostate cancer to receive approval by the U.S. Food and Drug Administra...
Jul 15th, 2011
A final decision memo issued on June 30 by the Centers for Medicare & Medicaid Services (CMS) provides Medicare patients with metastatic prostate cancer immediate access to a new treatment, and new hope. Autologous cellular immunotherapy, known clinically as sipuleucel-T, stimulates “the body’s natural defenses (such as the white blood cells called dendritic cells, T-lymphocytes ...
In CMS
May 13th, 2011
The July 1 quarterly HCPCS Level II update includes a handful of important drug/biological code changes. Effective July 1, HCPCS Level II code J7184 will be directly replaced with Q2041 Injection, Von Willebrand factor complex (human), Wilate, per 100 IU VWF RCo, which describes Wilate® for intravenous injection for spontaneous or trauma-induced bleeding in patients ...
In CMS
Apr 1st, 2011
The Centers for Medicare & Medicaid Services (CMS) announced March 30 that it would pay for Dendreon’s prostate cancer drug, Provenge, when used to treat Medicare beneficiaries with late-stage prostate cancer. The Food and Drug Administration (FDA) approved Provenge for patients with castration-resistant, metastatic prostate cancer in April 2010. In the absence of a national coverage ...
In Coding
Oct 1st, 2010
Quarterly updates to the Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment System (ASC PS) for separately paid drugs and biologicals, covered surgical procedures, and ancillary services have been released to Medicare contractors. The updates include one newly created pass-through device HCPCS Level II code, five newly created drug HCPCS Level II codes, and six ...